NCT06846606 - Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2028

Conditions

Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AMLRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Interventions

DRUG

AUTX-703

AUTX-703 administered orally

Trial Locations (9)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

19104

NOT_YET_RECRUITING

UPENN Perelman Center for Advanced Medicine, Philadelphia

27514

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

33612

NOT_YET_RECRUITING

H Lee Moffitt Cancer Center and Research Institute, Tampa

37203

RECRUITING

Sarah Cannon Center for Blood Cancer at TriStar Centennia, Nashville

43210

RECRUITING

Ohio State University, The James Comprehensive Cancer, Columbus

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope National Medical Center, Duarte